Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFOX vs mFOLFIRI in Refractory Biliary Tract Cancer
NCT03464968Phase 2Completed
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Jul 2015
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan in biliary tract cancer (BTC), sponsored by Seoul National University Bundang Hospital. Started Jul 2015; status: completed.
02
Drugs
irinotecan
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03464968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03464968.